THUNDEROBOT
872190
Ji Yao Holding Group
300108
Hangzhou Huasu Technology
301157
Flaircomm Microelectronics, Inc.
301600
Jiusheng Electric
301082
CN Stock MarketDetailed Quotes
688073 Bide Pharmatech
- 47.20
- -0.65-1.36%
Market Closed Jan 7 15:00 CST
4.29BMarket Cap53.58P/E (TTM)
48.90High45.87Low12.27KlotVolume47.47Open47.85Pre Close57.78MTurnover2.84%Turnover Ratio39.14P/E (Static)90.88MShares53.2852wk High2.15P/B2.04BFloat Cap28.5052wk Low57.42Limit Up43.23MShs Float112.07Historical High38.28Limit Down6.33%Amplitude28.50Historical Low0.90Dividend TTM47.10Avg Price6.83KlotAsk1.91%Div YieldTTM100Lot Size4.49KlotBid
Bide Pharmatech News
Bide Pharmaceutical: Self-inspection report on the 2024 Restricted Stock Incentive Plan insider\'s stock trading situation
Self-inspection report on the 2024 Restricted Stock Incentive Plan insider\'s stock trading situation
Bide Pharmaceutical: Explanation of the review opinions and disclosure of the supervisory board of Shanghai Bide Pharmaceutical Technology Co., Ltd. on the list of incentive recipients granted for the first time in the company\'s 2024 restricted stock incentive plan
Explanation of the review opinions and publicity of the board of supervisors of Shanghai Bide Pharmaceutical Technology Co., Ltd. on the list of incentive recipients granted for the first time in the company\'s 2024 restricted stock incentive plan
Bide Pharmaceuticals: Bide Pharmaceuticals: 2024 Restricted Stock Incentive Plan (Draft)
Bide Pharmaceuticals: 2024 Restricted Stock Incentive Plan (Draft)
2024 Restricted Stock Incentive Plan (Draft) Summary Announcement
The Company\'s 2024 Restricted Stock Incentive Plan granted a list of incentive recipients for the first time
Supervisory Board\'s Review Opinions on the Company\'s 2024 Restricted Stock Incentive Plan (Draft)
Legal Opinion of Shanghai Junlan Law Firm on Bidet Pharmaceuticals 2024 Restricted Stock Incentive Plan (Draft)
An indicative announcement on the actual controller of the company\'s proposal that the company repurchase shares again
Bide Pharmaceutical: Initial Public Offering Strategic Placement of Restricted Shares Listing and Circulation Announcement
Initial Public Offering Strategic Placement of Restricted Shares Listing and Circulation Notice
Announcement on the implementation results of share repurchase.
Announcement on the Progress of Repurchasing Shares through the Centralized Bidding Trading Method.
Announcement on the Completion of the Implementation of the Shareholding Plan by the Actual Controller and Director General Manager and the Results of the Shareholding
Announcement on the adjustment of the upper limit of the repurchase price after the implementation of the annual equity distribution in 2023.
Simplified Equity Change Report
Announcement on Shareholder Dissolution and Equity Changes
Announcement of Annual Equity Distribution Implementation in 2023